Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.1414
Abstract: Upadacitinib is a selective Janus kinase 1 inhibitor being developed for the treatment of several inflammatory autoimmune diseases, including rheumatoid arthritis. Upadacitinib is a nonsensitive substrate for metabolism by cytochrome P450 3A enzymes. This open‐label,… read more here.
Keywords: hepatic impairment; upadacitinib pharmacokinetics; effect; moderate hepatic ... See more keywords